Syndax Pharmaceuticals Reports Q1 Earnings with Strong Sales for Revuforj and Niktimvo
Syndax Pharmaceuticals reported combined net sales of over $100 million in the first quarter, driven by its products Revuforj ($49M) and Niktimvo ($55M). The company highlighted growth from NCCN guideline inclusion and an expanded FDA label for Revuforj. Despite short-term revenue challenges due to higher stem-cell transplant rates among KMT2A patients, management remains optimistic about long-term demand.
Tickers: $GLW
Topics: clinical_trials drug_sales earnings pharmaceuticals pipeline